Page results
-
Patient Advice and Liaison Service (PALS)
-
Information for service users about the RESPOND service for refugees and asylum seekers.
-
Information about the Integrated Women's Service at the RLHIM patient information leaflet
-
Outcome of National Institute for Health and Care Excellence (NICE) Technology Appraisal for Exagamglogene autotemcel (Exa-cel) for treating transfusion- dependent beta thalassaemia [ID4015] in individuals 12 years and over.
-
Information about the Integrated Children and Adolescent Service at the RLHIM
-
This page is for patients with obesity who are waiting for scheduled surgery.
-
Information about the Integrated Cancer Care Service for children and young adults at the RLHIM.
-
Pfizer Limited, in agreement with the Medicines Healthcare products Regulatory Agency (MHRA), has withdrawn the product, while a review of the benefits and risks is carried out.
-
Professor Manjit Matharu's major research interests include migraine, trigeminal autonomic cephalalgias, facial pain, neurostimulation for intractable headaches, spontaneous intracranial hypotension and other headache disorders in hypermobility syndromes.
-
What to expect from your neuro-oncology Clinical Nurse Specialist (key worker) at the NHNN
File results
-
FOI/2022/0764 - Patients treated for drinks spiked/ spiked by needle injection
-
FOI/2022/0768 - Patients treated for Haemophila A
-
FOI/2022/0770 - Parking operations, impact, and parking charge notices issued
-
FOI/2022/0772 - Treatments for rare diseases
-
FOI/2022/0774 - Pre-pregnancy counselling clinics with consultant-led maternity units for women with medical problems
-
FOI/2022/0775 - Data on COVID-19 infections and related illness in staff
-
FOI/2022/0781 - Protocols for diagnosis and treatment of non-small cell lung cancer
-
FOI/2022/0782 - Digital dictation, voice recognition software and outsourced transcription services
-
FOI/2022/0783 - Separate units/ beds allocated for delivery of CAR-T therapy and BMT services
-
FOI/2022/0785 - Patient treatment with Nivolumab